Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT00262925 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

12

Enrollment

NIH

Sponsor class

Stopped slow accrual

Conditions

Recurrent Adult Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL: alemtuzumab
DRUG: asparaginase
DRUG: methotrexate
DRUG: dexamethasone
DRUG: leucovorin calcium
DRUG: mercaptopurine
DRUG: vincristine

Sponsor

National Cancer Institute (NCI)